Status:
COMPLETED
Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis
Lead Sponsor:
Carmel Medical Center
Collaborating Sponsors:
Technion, Israel Institute of Technology
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Multiple Sclerosis (MS) is the most common chronic neurological disease affecting young adults, with onset usually at the age 20-40 years. The disease is characterized by two main phenotypes: Relapse-...
Detailed Description
BACKGROUND Multiple Sclerosis (MS) is the most common chronic neurological disease affecting young adults, with onset usually at the age 20-40 years. The disease is characterized by two main phenotype...
Eligibility Criteria
Inclusion
- Individuals willing and able to give informed consent
- MS group:
- Male or females diagnosed with MS Age 18-75 years
- Control subjects:
- Healthy volunteers: individuals that do not have MS or any other condition that is defined as "autoimmune"
Exclusion
- Pregnant women
- Presence of a serious infectious disease (e.g. HIV, viral hepatitis and similar contagious diseases).
- Withdrawal criteria:
- Any new clinical information that is not consistent with inclusion criteria.
- Technical problems in the performance of the tests.
Key Trial Info
Start Date :
December 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 2 2022
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT04074629
Start Date
December 16 2019
End Date
August 2 2022
Last Update
December 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ariel Miller
Haifa, Israel, 34362